BWX Technologies (BWXT) Expected to Announce Quarterly Earnings on Monday

BWX Technologies (NYSE:BWXT) will likely be issuing its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect the company to announce earnings of $0.92 per share and revenue of $828.4650 million for the quarter. BWX Technologies has set its FY 2026 guidance at 4.550-4.700 EPS. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 4, 2026 at 5:00 PM ET.

BWX Technologies (NYSE:BWXT) last issued its earnings results on Monday, February 23rd. The technology company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.17. The business had revenue of $885.84 million for the quarter, compared to the consensus estimate of $837.47 million. BWX Technologies had a net margin of 10.28% and a return on equity of 30.94%. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.92 earnings per share. On average, analysts expect BWX Technologies to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

BWX Technologies Price Performance

Shares of BWXT opened at $223.54 on Monday. The company has a market cap of $20.48 billion, a price-to-earnings ratio of 62.62, a PEG ratio of 3.85 and a beta of 0.80. BWX Technologies has a 1-year low of $102.42 and a 1-year high of $241.82. The company’s fifty day simple moving average is $211.42 and its 200 day simple moving average is $199.01. The company has a current ratio of 2.32, a quick ratio of 2.25 and a debt-to-equity ratio of 1.64.

BWX Technologies Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 27th. Investors of record on Wednesday, March 11th were issued a dividend of $0.27 per share. The ex-dividend date was Wednesday, March 11th. This is a positive change from BWX Technologies’s previous quarterly dividend of $0.25. This represents a $1.08 dividend on an annualized basis and a yield of 0.5%. BWX Technologies’s dividend payout ratio is presently 30.25%.

Wall Street Analyst Weigh In

A number of research firms have commented on BWXT. BTIG Research lifted their price objective on shares of BWX Technologies from $225.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen cut shares of BWX Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Zacks Research raised shares of BWX Technologies from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Truist Financial set a $205.00 price objective on shares of BWX Technologies in a research report on Friday, January 9th. Finally, Bank of America lifted their price objective on shares of BWX Technologies from $230.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $207.60.

Insiders Place Their Bets

In other news, CAO Kevin James Gorman sold 1,344 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $214.71, for a total value of $288,570.24. Following the completion of the sale, the chief accounting officer owned 114 shares of the company’s stock, valued at approximately $24,476.94. The trade was a 92.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gerhard F. Burbach sold 1,983 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $208.61, for a total transaction of $413,673.63. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,327 shares of company stock valued at $2,734,844 over the last ninety days. 0.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BWX Technologies

Institutional investors have recently modified their holdings of the business. WFA of San Diego LLC bought a new stake in shares of BWX Technologies in the second quarter valued at about $29,000. Ancora Advisors LLC bought a new stake in shares of BWX Technologies in the third quarter valued at about $49,000. Quarry LP boosted its position in shares of BWX Technologies by 158.3% in the fourth quarter. Quarry LP now owns 359 shares of the technology company’s stock valued at $62,000 after acquiring an additional 220 shares during the period. Rakuten Securities Inc. boosted its position in shares of BWX Technologies by 309.7% in the second quarter. Rakuten Securities Inc. now owns 463 shares of the technology company’s stock valued at $67,000 after acquiring an additional 350 shares during the period. Finally, Greenline Wealth Management LLC bought a new stake in shares of BWX Technologies in the fourth quarter valued at about $69,000. Institutional investors own 94.39% of the company’s stock.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.